Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01205815 · ClinicalTrials.gov registry record
Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment
A clinical trial of Melanoma, sponsored by Vanderbilt-Ingram Cancer Center.
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 1
- Study location
NCT01205815 is a study of Melanoma that is actively recruiting participants, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 3,000 participants, above the 695-participant average among 266 other Melanoma trials with a reported enrollment target (332% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01205815, a study of Melanoma, is actively recruiting participants, sponsored by Vanderbilt-Ingram Cancer Center.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to identify biological characteristics occurring in the initiation and progression of melanoma.
Conditions Studied
Interventions
- OTHER Tissue and blood collection
Study Locations (1)
Tennessee
- Vanderbitl-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2010-06-03 |
| Est. Completion | 2027-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01205815
The ClinicalTrials.gov registry entry for NCT01205815 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 695-participant average among 266 other Melanoma trials with a reported enrollment target (332% higher). The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Tissue and blood collection is the first listed.
NCT01205815 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT01205815 about?
NCT01205815 is a clinical study titled "Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment". The purpose of this research is to identify biological characteristics occurring in the initiation and progression of melanoma.
What is the current status of trial NCT01205815?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2010-06-03. Estimated completion is 2027-06.
What conditions does trial NCT01205815 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT01205815?
The interventions under investigation include: Tissue and blood collection (OTHER).
Who is sponsoring clinical trial NCT01205815?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01205815 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.